Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-01-05

FDA Approved: AZOR — Supplemental Application (Cosette Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for AZOR (amlodipine besylate and olmesartan medoxomil) from Cosette Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AZOR (Amlodipine besylate and olmesartan medoxomil)

Snippet

SUPPL AP for AZOR (AMLODIPINE BESYLATE AND OLMESARTAN MEDOXOMIL)